Sonova enters strategic alliance with French biotech company to treat hearing loss
In December last year, Sonova dished out almost EUR 5m to Sensorion, a French biotech company specialized in the treatment of hearing disorders. Now, the two companies are entering into a strategic partnership with the goal of improving diagnostics and treatment through genetic analysis.
Arnd Kaldowsk, CEO at Sonova | Photo: Sonova / PR/Daniel Hager Photography & Film
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN
A French-Swiss alliance for hearing loss treatment has been formed.
Two phase III trials give the Danish dermatology company hope to see tralokinumab’s approved indication expanded to include the younger segment of teens.
Novo Nordisk, which has been ousted from UK pharma group ABPI for two years, does not want to comment further on its punishment for misleading marketing.
The lack of support for GN’s scrapped capital raise was to be anticipated, says a DNB analyst, meaning it would have made sense to make a plan B in advance.
Novo Nordisk has been suspended due to misleading marketing that breached the Code of Practice of the Association of the British Pharmaceutical Industry.
Microsoft is in the process of discontinuing Internet Explorer – and so are we. For a better experience, we recommend using one of the following browsers.